| 股票代码：002728 | 股票简称：特一药业 | 公告编号：2023-033 | | --- | --- | --- | | 债券代码：128025 | 债券简称：特一转债 | | （问题征集专题页面二维码） 特此公告。 特一药业集团股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司定于 2023 年 5 月 10 日（周三）15:00-17:00 在全景网举 办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理许丹青先生、副董事长兼副总经理 许松青先生、财务负责人兼董事会秘书陈习良先生、董事卢北京先生、独立董事曹艳铭 女士、东莞证券保荐代表人郭文俊先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 ...

Financial Performance - The company's operating revenue for 2022 was CNY 886,570,938.60, representing a 16.94% increase compared to CNY 758,160,497.71 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 178,204,104.28, a 40.41% increase from CNY 126,917,422.27 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 171,371,215.85, which is a 51.54% increase from CNY 113,083,086.36 in 2021[20]. - The net cash flow from operating activities was CNY 371,658,160.26, up 44.72% from CNY 256,814,750.48 in the previous year[20]. - The basic earnings per share for 2022 was CNY 0.80, reflecting a 29.03% increase from CNY 0.62 in 2021[20]. - Total assets at the end of 2022 amounted to CNY 2,545,604,654.93, a 23.20% increase from CNY 2,066,196,431.51 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,403,139,439.55, an 11.21% increase from CNY 1,261,690,115.09 in 2021[20]. - The weighted average return on equity for 2022 was 13.98%, an increase of 2.38% from 11.60% in 2021[20]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 6.50 per 10 shares, along with a capital reserve increase of 4 shares for every 10 shares held[4]. - The total cash dividend amount for the reporting period is ¥159,514,247.75, which represents 36.34% of the total distributable profit of ¥438,924,757.50[163][160]. - The proposed cash dividend distribution is ¥6.50 per 10 shares (including tax), along with a capital reserve increase of 4 shares for every 10 shares held[162][163]. - The company's profit distribution policy cannot be changed arbitrarily and must be approved by the board and shareholders if adjustments are necessary due to operational conflicts[157]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a shift towards high-quality development, providing opportunities for the company amidst ongoing reforms[29]. - The aging population in China reached 19.8% by the end of 2022, increasing the demand for pharmaceutical products and services[32]. - The company is navigating a complex competitive landscape in the pharmaceutical industry, which presents both challenges and opportunities for growth[32]. Product Development and R&D - The company focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, positioning itself strategically in the healthcare sector[33]. - The company has 31 invention patents, 33 design patents, and 8 utility model patents as of the end of the reporting period[39]. - Research and development expenses for 2022 were ¥38,009,796.53, a slight increase of 0.62% compared to 2021[62]. - The company has initiated clinical trials for the Skin Disease Blood Detox Pill, aiming to enhance its product portfolio[40]. - The company is committed to the innovation and development of traditional Chinese medicine, aligning with national policies to promote its growth[96]. Sales and Marketing Strategy - The company plans to shift from a distributor model to direct sales to retail terminals to enhance marketing channel effectiveness[38]. - The company’s marketing strategy has been adjusted to increase market expansion and promotional efforts, leading to improved sales performance[42]. - The company aims to enhance marketing capabilities and expand the market share of "Zhi Ke Bao Pian" by deepening existing markets and exploring new ones[98]. Environmental Compliance and Sustainability - The company has made continuous investments in environmental protection to reduce resource consumption and pollution[184]. - The company has a wastewater treatment capacity of 240 tons per day, achieving surface IV class standards for treated wastewater[185]. - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until 2026 and 2027[181]. - The company emphasizes employee rights protection, adhering to labor laws and engaging employees in decision-making processes[195]. Governance and Shareholder Rights - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[126]. - The company actively expands communication channels with investors to ensure fair and timely information disclosure, maintaining the rights of shareholders and stakeholders[126]. - The company has established a performance evaluation system for senior management, ensuring that compensation reflects job responsibilities and performance[170]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[114]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of up to 200 million allocated for this purpose[114]. - The overall market outlook remains positive, with anticipated growth driven by increasing demand for healthcare products and services[114].

Financial Performance - The company's revenue for Q1 2023 reached ¥304,157,421.18, representing a 56.50% increase compared to ¥194,348,090.18 in the same period last year[3] - Net profit attributable to shareholders was ¥105,470,920.94, a significant increase of 130.96% from ¥45,666,688.38 year-on-year[3] - Basic earnings per share rose to ¥0.46, up 119.05% from ¥0.21 in the previous year[3] - Operating profit for the quarter was CNY 127,043,924.70, compared to CNY 54,538,015.75 in Q1 2022, marking an increase of 133.3%[15] - The company’s total comprehensive income for the quarter was CNY 105,470,920.94, up from CNY 45,666,688.38 in the same period last year, indicating a growth of 131.3%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,498,981,899.98, a decrease of 1.83% from ¥2,545,604,654.93 at the end of the previous year[3] - Cash and cash equivalents at the end of Q1 2023 totaled ¥700,881,200.19, down from ¥739,660,362.06 at the beginning of the year[10] - Total assets as of March 31, 2023, were ¥2,498,981,899.98, a decrease from ¥2,545,604,654.93 at the beginning of the year[12] - Total liabilities decreased to ¥989,721,619.89 from ¥1,142,465,215.38 at the start of the year[12] - The company's equity attributable to shareholders increased to ¥1,509,260,280.09, up from ¥1,403,139,439.55 at the beginning of the year[12] Cash Flow - The company reported a net cash flow from operating activities of ¥26,912,422.14, slightly up by 1.02% from ¥26,640,062.41[3] - Cash flow from operating activities generated a net inflow of CNY 26,912,422.14, slightly up from CNY 26,640,062.41 in the previous year[16] - The net cash outflow from investing activities was CNY -19,235,255.51, compared to CNY -63,112,412.77 in the same period last year[17] - Cash inflow from financing activities totaled CNY 63,918,749.00, a decrease from CNY 229,000,000.00 in Q1 2022[17] Costs and Expenses - Total operating costs for Q1 2023 were ¥180,960,104.90, up 29.2% from ¥140,109,023.79 in Q1 2022[14] - Research and development expenses increased to ¥10,182,147.51, reflecting a rise of 17.7% from ¥8,650,287.50 in the previous year[14] - The company incurred a tax expense of CNY 21,553,510.03, compared to CNY 8,718,235.87 in the previous year, reflecting a growth of 147.0%[15] Market and Growth Strategy - The increase in revenue was primarily driven by a significant rise in pharmaceutical sales, contributing to a gross profit margin increase[5] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[5] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[11] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,464, with the largest shareholder holding 31.16% of the shares[7]

Group 1: Company Overview - The company is named Te Yi Pharmaceutical Group Co., Ltd., previously known as Tai Cheng Pharmaceutical [1][12] - The company held an investor relations activity on April 11, 2017, to discuss performance [1] Group 2: Financial Plans and Performance - The company plans to issue convertible bonds, pending shareholder approval [2] - As of December 31, 2016, the company had a total debt of ¥716.61 million and paid ¥17.33 million in interest for the year [7] - The net profit for 2016 was ¥94.78 million, representing a year-on-year growth of 16.86% [11][12] Group 3: Market Position and Sales - Major sales regions include South China (¥276 million, 42.04% of total sales), East China (¥118 million, 18.02%), Northeast (¥68 million, 10.37%), and Central China (¥61 million, 9.27%) [9] - The company maintains stable relationships with its top customers [10] Group 4: Industry Challenges and Opportunities - The company faces challenges due to increased regulation on drug prices and quality, but this also presents opportunities for stronger companies [3] - The company is considering mergers and acquisitions to enhance competitiveness and risk resistance [4] Group 5: Innovation and Development - The company has not established plans for a merger fund but is open to future opportunities [2] - There are no current plans to explore new fields outside the pharmaceutical industry [6] Group 6: Investor Relations and Shareholder Returns - The company aims to continuously reward shareholders through dividends and other means within regulatory frameworks [8] - The company is committed to improving its market value management and enhancing shareholder returns [10]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 300,100,208.56, a decrease of 37.22% compared to CNY 478,018,794.94 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 27,390,192.54, down 70.00% from CNY 91,313,020.55 in the previous year[19]. - The net cash flow from operating activities was CNY 56,096,576.03, a decline of 44.62% compared to CNY 101,300,962.38 in the same period last year[19]. - The basic earnings per share decreased to CNY 0.13, down 71.11% from CNY 0.45 in the previous year[19]. - The total comprehensive income for the first half of 2020 was CNY 26,351,477.54, compared to CNY 102,450,779.52 in the same period of 2019, indicating a significant decrease[171]. - The total comprehensive income for the first half of 2020 was 3,020 million, reflecting a decrease of 9.49% compared to the previous period[190]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,148,844,182.40, a decrease of 4.78% from CNY 2,256,808,633.65 at the end of the previous year[19]. - The company's total liabilities increased to CNY 1,124,605,907.13, up from CNY 952,107,480.07 year-over-year[161]. - The owner's equity totaled CNY 1,025,732,499.68, a decrease from CNY 1,116,221,394.04 in the previous year[161]. - The total liabilities at the end of the first half of 2020 were reported at 913,061,087, indicating a stable financial position[193]. Research and Development - The company emphasizes research and development as a driving force for growth, collaborating with research institutions to enhance drug quality and efficacy[36]. - The company has a total of 29 invention patents, 37 design patents, and 4 utility model patents as of the end of the reporting period[36]. - The company established a wholly-owned subsidiary, Te Yi Pharmaceutical Research (Guangdong) Co., Ltd., to strengthen its R&D capabilities[36]. - The company is actively pursuing consistency evaluations for generic drugs, with one product already completed and others in progress[49]. Market and Sales Strategy - The company focuses on the pharmaceutical manufacturing industry, primarily engaged in the R&D, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials[26]. - The sales model primarily relies on distributors, with a focus on increasing sales to large and medium-sized chain pharmacies and grassroots medical institutions[35]. - The company plans to enhance brand building through advertising across various media platforms to increase brand awareness and competitiveness[48]. - The company aims to expand its marketing channels and improve market coverage by developing untapped markets and refining existing distributor management[49]. Financial Management and Investments - The company reported a significant increase in other receivables, primarily due to increased business turnover funds[39]. - The net amount of investment income from financial products and bank deposits, after deducting bank fees, is RMB 18,921,632.83, with RMB 1,755,456.75 received in the current period[67]. - The company has temporarily used RMB 50 million of idle raised funds to supplement working capital, with a repayment timeline not exceeding 12 months[71]. - The company purchased bank financial products with an investment balance of RMB 35 million as of June 30, 2020[72]. Risks and Challenges - The company faces risks from industry policy changes, including stricter regulations and price controls, which could impact future growth[80]. - The outbreak of COVID-19 in early 2020 poses significant challenges to the company's operational performance and may lead to substantial declines[84]. - The company has outlined potential risks and corresponding measures in its report, which investors are encouraged to review[5]. Shareholder Information - The largest shareholder, Xu Danqing, holds 30.51% of the shares, totaling 62,100,000 shares, with a pledge status[122]. - The total number of shares increased from 200,908,121 to 203,517,305 due to the conversion of convertible bonds[117]. - The company has a total of 203,517,305 ordinary shareholders at the end of the reporting period[122]. - The proportion of limited sale shares decreased from 40.35% to 39.84%, while the proportion of unrestricted shares increased from 59.65% to 60.16%[117]. Corporate Governance - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[125]. - The company has not reported any significant changes in shareholding or shareholder situations during the reporting period[115]. - The company has not conducted any significant asset or equity acquisitions during the reporting period[99]. - The company has not implemented any employee incentive plans during the reporting period[97].

Financial Performance - Operating revenue for the period was CNY 80,181,639.22, a 2.47% increase year-on-year[7] - Net profit attributable to shareholders decreased by 18.01% to CNY 17,056,912.52 compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses fell by 23.43% to CNY 15,928,499.39[7] - Basic and diluted earnings per share were both CNY 0.19, down 32.14% year-on-year[7] - The weighted average return on equity was 2.82%, a decrease of 56.23% compared to the previous year[7] - The company's net profit attributable to shareholders for 2014 is expected to range from ¥80.55 million to ¥88.61 million, reflecting a growth of 0.00% to 10.00% compared to the previous year[17] Asset and Shareholder Information - Total assets increased by 81.05% to CNY 821,142,355.45 compared to the end of the previous year[7] - Net assets attributable to shareholders rose by 105.58% to CNY 719,806,129.55 year-on-year[7] - The total number of ordinary shareholders at the end of the reporting period was 13,557[10] - The largest shareholder, Xu Danqing, holds 31.05% of the shares, totaling 31,050,000 shares[10] Cash Flow and Financial Activities - Cash flow from operating activities for the year-to-date was CNY 56,515,623.00, an increase of 68.55%[7] - The company's cash and cash equivalents increased by 213.45%, reaching ¥510.31 million due to funds raised from a public stock offering[14] - The net cash flow from operating activities increased by 68.55% to ¥56.52 million, attributed to higher cash receipts from sales[14] - The net cash flow from financing activities improved by 33.77%, with a net outflow of -¥15.79 million, reflecting reduced payments for construction projects[14] - The company reported a 2100.07% increase in net cash flow from investing activities, totaling ¥306.78 million, due to funds raised from the public stock offering[14] Expenses and Income - Sales expenses rose by 34.16% to ¥22.77 million, primarily due to increased advertising expenditures[14] - The company reported a significant increase in other income, which rose by 5971.00% to ¥2.43 million, driven by increased government subsidies[14] - The capital reserve increased by 721.82% to ¥337.93 million, resulting from the premium on shares issued during the public offering[14] - The company experienced a 57.85% increase in financial income, with a net financial expense of -¥3.32 million due to growth in interest income[14] - Prepayments increased by 38.16% to ¥25.06 million, attributed to increased advance payments for raw material purchases[14]